• Home
  • R&D
  • FINANCE
  • MANUFACTURING
  • APPROVALS
  • SUPPLY CHAIN
  • LAUNCHES
  • EVENTS
    • EVENTS NEWS
    • EVENT LISTINGS
  • APPOINTMENTS
Search
Logo
  • About us
  • Marketing
  • Contact Us
  • Newsletter
  • Cookie Policy
  • Terms & Conditions
  • Data Privacy Policy
Facebook
Linkedin
Twitter
Logo
  • Home
  • R&D
  • FINANCE
  • MANUFACTURING
  • APPROVALS
  • SUPPLY CHAIN
  • LAUNCHES
  • EVENTS
    • EVENTS NEWS
    • EVENT LISTINGS
  • APPOINTMENTS
Home

Loading view.
  • There are no upcoming events.
  • There are no upcoming events.

Events Search and Views Navigation

Event Views Navigation

  • List
Today
  • Today
  • Google Calendar
  • iCalendar
  • Outlook 365
  • Outlook Live
  • Export .ics file
  • Export Outlook .ics file

News

Laverock Therapeutics raises £13.5m to develop unique gene silencing platform for programmable advanced therapies

29th September 2023
Laverock Therapeutics, established in 2021 to commercialise the gene editing induced gene silencing (GEiGS) platform for all human therapeutic applications, has expanded its seed...

LEQEMBI Intravenous Infusion approved in Japan as treatment for slowing progression of mild cognitive...

29th September 2023
Eisai and Biogen's humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI Intravenous Infusion” (200 mg, 500mg, lecanemab) has been approved in Japan as a...

US FDA approves Jardiance to treat adults with chronic kidney disease

29th September 2023
The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim and Eli Lilly and Company's Jardiance (empagliflozin) 10 mg tablets to reduce the...
Logo

© 2021 Part of the Business Link Magazine Group. Armstrong House, Armstrong Street, Grimsby,
North East Lincolnshire, DN31 2QE

Facebook
Linkedin
Twitter

About Us

  • About us
  • Marketing
  • Contact Us
  • Newsletter
  • Cookie Policy
  • Terms & Conditions
  • Data Privacy Policy

Popular Category

  • R&D313
  • APPROVALS229
  • Finance208
  • MANUFACTURING48
  • SUPPLY CHAIN18
  • Launches16

Editor Picks

University spinout company Crucible Therapeutics raises £5m to advance pioneering treatments for neurological diseases